Daylight-mediated Photodynamic Therapy of Actinic Keratoses: a Randomized, Double-blinded Pilot Study Comparing Topical 0.2% Hexylaminolaevulinate With 16% Methylaminolaevulinate

Trial Profile

Daylight-mediated Photodynamic Therapy of Actinic Keratoses: a Randomized, Double-blinded Pilot Study Comparing Topical 0.2% Hexylaminolaevulinate With 16% Methylaminolaevulinate

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Jul 2016

At a glance

  • Drugs Hexyl aminolevulinate (Primary) ; Methyl aminolevulinate
  • Indications Actinic keratosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 May 2016 Status changed from recruiting to completed.
    • 04 Dec 2014 Drug concentration in the experimental treatment arm (hexyl-aminolevulinate) has been changed from 2% to 0.2% and 2% as reported by ClinicalTrials.gov record.
    • 04 Dec 2014 Planned End Date changed from 1 Dec 2015 to 1 May 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top